MYL4 and SDHA have been identified as upstream regulators of RPL3l, highlighting the potential of targeting the MYL4-SDHA-RPL3l axis as a new strategy for mitigating cardiac remodeling and treating HF (84) (Supplementary Table S1). This evidence concerns the gene RPL3L and hydrops fetalis.